
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, p
Keywords: adalimumab; efficacy; guselkumab; interleukin-23; psoriasis; safety; switching; VOYAGE 1; VOYAGE 2; AE; adverse event; DLQI; Dermatology Life Quality Index; IGA; Investigator Global Assessment; IL; interleukin; ISR; injection site reaction; MACE; major ad